High-Sensitivity Troponin

Cardiac troponins are structural proteins found exclusively in heart muscle cells (cardiomyocytes), where they play an essential role in regulating the calcium-dependent contraction of the heart. When cardiomyocytes are injured — whether through ischemia, inflammation, or mechanical stress — troponin molecules are released into the bloodstream. High-sensitivity assays can detect these proteins at concentrations 10 to 100 times lower than conventional troponin tests, measured in nanograms per liter (ng/L) rather than micrograms per liter.

There are two clinically relevant isoforms: cardiac troponin I (cTnI) and cardiac troponin T (cTnT). While both are specific to heart muscle, they are measured by different assay platforms. The "high-sensitivity" designation refers to the analytical performance of the assay rather than a different protein — these tests can reliably quantify troponin at the 99th percentile of a healthy reference population, which is the recommended diagnostic threshold for myocardial infarction.

Because hs-troponin assays detect measurable levels in the majority of healthy individuals, they have expanded the clinical utility of troponin beyond acute myocardial infarction diagnosis. Baseline troponin concentrations, even within the "normal" range, have been associated with long-term cardiovascular risk in population studies, positioning hs-troponin as both an acute diagnostic marker and a potential prognostic indicator.

Prevena Health is investigating whether continuous troponin monitoring through a wearable biosensor may support earlier awareness of myocardial stress. Current clinical practice relies on troponin measurements taken in emergency or hospital settings — typically after symptoms have already prompted a patient to seek care. Continuous surveillance aims to capture troponin trends in the ambulatory setting, potentially identifying subclinical elevations before they reach acute thresholds.

This research direction may be particularly relevant for high-risk populations, including patients with known coronary artery disease, those undergoing cardiotoxic therapies, or individuals recovering from cardiac procedures. By providing longitudinal troponin trend data, Prevena's platform may support clinicians in making more informed decisions about the timing and intensity of cardiac monitoring.